Catalogue Search | MBRL
Search Results Heading
Explore the vast range of titles available.
MBRLSearchResults
-
DisciplineDiscipline
-
Is Peer ReviewedIs Peer Reviewed
-
Reading LevelReading Level
-
Content TypeContent Type
-
YearFrom:-To:
-
More FiltersMore FiltersItem TypeIs Full-Text AvailableSubjectCountry Of PublicationPublisherSourceTarget AudienceDonorLanguagePlace of PublicationContributorsLocation
Done
Filters
Reset
53,832
result(s) for
"Clinical chemistry"
Sort by:
Patient-Based Real-Time Quality Control: Review and Recommendations
2019
For many years the concept of patient-based quality control (QC) has been discussed and implemented in hematology laboratories; however, the techniques have not been widely implemented in clinical chemistry. This is mainly because of the complexity of this form of QC, as it needs to be optimized for each population and often for each analyte. However, the clear advantages of this form of QC, together with the ongoing realization of the shortcomings of “conventional” QC, have driven a need to provide guidance to laboratories to assist in deploying patient-based QC. This overview describes the components of a patient-based QC system (calculation algorithm, block size, truncation limits, control limits) and the relationship of these to the analyte being controlled. We also discuss the need for patient-based QC system optimization using patient data from the individual testing laboratory to reliably detect systematic errors while ensuring that there are few false alarms. The term patient-based real-time quality control covers many activities that use data from patient samples to detect analytical errors. These activities include the monitoring of patient population parameters such as the mean or median analyte value or using single within-patient changes such as the delta check. In this report, we will restrict the discussion to population-based parameters. This overview is intended to serve as a guide for the implementation of a patient-based QC system. The report does not cover the clinical evaluation of the population.
Journal Article
Love sense : the revolutionary new science of romantic relationships
The bestselling author of Hold Me Tight presents a revolutionary new understanding of why and how we love, based on cutting-edge research.
The Biological Variation Data Critical Appraisal Checklist: A Standard for Evaluating Studies on Biological Variation
by
Álvarez, Virtudes
,
Jonker, Niels
,
Aslan, Berna
in
Alanine
,
Alanine transaminase
,
Alanine Transaminase - blood
2018
Concern has been raised about the quality of available biological variation (BV) estimates and the effect of their application in clinical practice. A European Federation of Clinical Chemistry and Laboratory Medicine Task and Finish Group has addressed this issue. The aim of this report is to (
) describe the Biological Variation Data Critical Appraisal Checklist (BIVAC), which verifies whether publications have included all essential elements that may impact the veracity of associated BV estimates, (
) use the BIVAC to critically appraise existing BV publications on enzymes, lipids, kidney, and diabetes-related measurands, and (
) apply metaanalysis to deliver a global within-subject BV (CV
) estimate for alanine aminotransferase (ALT).
In the BIVAC, publications were rated as A, B, C, or D, indicating descending compliance for 14 BIVAC quality items, focusing on study design, methodology, and statistical handling. A D grade indicated that associated BV estimates should not be applied in clinical practice. Systematic searches were applied to identify BV studies for 28 different measurands.
In total, 128 publications were identified, providing 935 different BV estimates. Nine percent achieved D scores. Outlier analysis and variance homogeneity testing were scored as C in >60% of 847 cases. Metaanalysis delivered a CV
estimate for ALT of 15.4%.
Application of BIVAC to BV publications identified deficiencies in required study detail and delivery, especially for statistical analysis. Those deficiencies impact the veracity of BV estimates. BV data from BIVAC-compliant studies can be combined to deliver robust global estimates for safe clinical application.
Journal Article
The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases
by
Orrù, Christina D
,
Schmitz, Matthias
,
Schulz-Schaeffer, Walter J
in
631/1647/2196/2197
,
631/378/1689
,
631/80/470/460
2016
This 96-well-plate ‘real-time quaking-induced conversion’ assay allows the detection of abnormal prion protein in human brain and CSF samples. It can be applied to study many protein misfolding diseases, as well as for drug screening and prion strain discrimination.
The development and adaption of
in vitro
misfolded protein amplification systems has been a major innovation in the detection of abnormally folded prion protein scrapie (PrP
Sc
) in human brain and cerebrospinal fluid (CSF) samples. Herein, we describe a fast and efficient protein amplification technique, real-time quaking-induced conversion (RT-QuIC), for the detection of a PrP
Sc
seed in human brain and CSF. In contrast to other
in vitro
misfolded protein amplification assays—such as protein misfolding cyclic amplification (PMCA)—which are based on sonication, the RT-QuIC technique is based on prion seed–induced misfolding and aggregation of recombinant prion protein substrate, accelerated by alternating cycles of shaking and rest in fluorescence plate readers. A single RT-QuIC assay typically analyzes up to 32 samples in triplicate, using a 96-well-plate format. From sample preparation to analysis of results, the protocol takes ∼87 h to complete. In addition to diagnostics, this technique has substantial generic analytical applications, including drug screening, prion strain discrimination, biohazard screening (e.g., to reduce transmission risk related to prion diseases) and the study of protein misfolding; in addition, it can potentially be used for the investigation of other protein misfolding diseases such as Alzheimer's and Parkinson's disease.
Journal Article
Gold nanoparticles for the development of clinical diagnosis methods
by
Pereira, Eulália
,
Miranda, Adelaide
,
Gomes, Inês
in
analysis
,
Analytical Chemistry
,
antibodies
2008
The impact of advances in nanotechnology is particularly relevant in biodiagnostics, where nanoparticle-based assays have been developed for specific detection of bioanalytes of clinical interest. Gold nanoparticles show easily tuned physical properties, including unique optical properties, robustness, and high surface areas, making them ideal candidates for developing biomarker platforms. Modulation of these physicochemical properties can be easily achieved by adequate synthetic strategies and give gold nanoparticles advantages over conventional detection methods currently used in clinical diagnostics. The surface of gold nanoparticles can be tailored by ligand functionalization to selectively bind biomarkers. Thiol-linking of DNA and chemical functionalization of gold nanoparticles for specific protein/antibody binding are the most common approaches. Simple and inexpensive methods based on these bio-nanoprobes were initially applied for detection of specific DNA sequences and are presently being expanded to clinical diagnosis. [graphic removed]
Journal Article
Quantifying the Added Value of a Diagnostic Test or Marker
by
Reitsma, Johannes B
,
Bossuyt, Patrick M M
,
Linnet, Kristian
in
Accuracy
,
Analytical, structural and metabolic biochemistry
,
Area Under Curve
2012
In practice, the diagnostic workup usually starts with a patient with particular symptoms or signs, who is suspected of having a particular target disease. In a sequence of steps, an array of diagnostic information is commonly documented. The diagnostic information conveyed by different results from patient history, physical examination, and subsequent testing is to varying extents overlapping and thus mutually dependent. This implies that the diagnostic potential of a test or biomarker is conditional on the information obtained from previous tests. A key question about the accuracy of a diagnostic test/biomarker is whether that test improves the diagnostic workup beyond already available diagnostic test results. This second report in a series of 4 gives an overview of several methods to quantify the added value of a new diagnostic test or biomarker, including the area under the ROC curve, net reclassification improvement, integrated discrimination improvement, predictiveness curve, and decision curve analysis. Each of these methods is illustrated with the use of empirical data. We reiterate that reporting on the relative increase in discrimination and disease classification is relevant to obtain insight into the incremental value of a diagnostic test or biomarker. We also recommend the use of decision-analytic measures to express the accuracy of an entire diagnostic workup in an informative way.
Journal Article
Applications of MALDI Mass Spectrometry in Clinical Chemistry
by
Duncan, Mark W
,
Nedelkov, Dobrin
,
Walsh, Ryan
in
Advantages
,
Chemistry
,
Chemistry, Clinical - economics
2016
MALDI-TOF mass spectrometry (MS) is set to make inroads into clinical chemistry because it offers advantages over other analytical platforms. These advantages include low acquisition and operating costs, ease of use, ruggedness, and high throughput. When coupled with innovative front-end strategies and applied to important clinical problems, it can deliver rapid, sensitive, and cost-effective assays.
This review describes the general principles of MALDI-TOF MS, highlights the unique features of the platform, and discusses some practical methods based upon it. There is substantial potential for MALDI-TOF MS to make further inroads into clinical chemistry because of the selectivity of mass detection and its ability to independently quantify proteoforms.
MALDI-TOF MS has already transformed the practice of clinical microbiology and this review illustrates how and why it is now set to play an increasingly important role in in vitro diagnostics in particular, and clinical chemistry in general.
Journal Article
Effects of Orally Consumed Rosa damascena Mill. Hydrosol on Hematology, Clinical Chemistry, Lens Enzymatic Activity, and Lens Pathology in Streptozotocin-Induced Diabetic Rats
by
Kartal, Murat
,
Nuhoğlu, Fadime
,
Demirbolat, İlker
in
aldose reductase
,
Animals
,
Binding Sites
2019
Diabetes mellitus is a multisystemic metabolic disorder that may affect the eyes, kidneys, vessels, and heart. Chronic hyperglycemia causes non-enzymatic glycation of proteins and elevation of the polyol pathway resulting in oxidative stress that damages organs. The current study aimed to investigate the dose-dependent effects of orally consumed Rosa damascena Mill. hydrosol on hematology, clinical biochemistry, lens enzymatic activity, and lens pathology in streptozotocin (STZ)-induced diabetic rats. Diabetes was induced into male Sprague–Dawley rats by intraperitoneal administration of STZ (40 mg/kg body weight). Rose hydrosols containing 1515 mg/L and 500 mg/L total volatiles (expressed as citronellol) were introduced to rats orally for 45 days. Consumption of 1515 mg/L volatile containing rose hydrosol successfully ameliorated hematologic, hepatic, and renal functions. Hydrosols also attenuated hyperglycemia and decreased the advanced glycation end-product formation in a dose-dependent manner. Rose hydrosol components significantly increased the lens enzymatic activities of glutathione peroxidase and decreased the activity of aldose reductase to prevent cataractogenesis. Histopathological examinations of rat lenses also indicated that increasing the dose of rose hydrosol had a protective effect on lenses in diabetic conditions. Additionally, in silico modeling of aldose reductase inhibition with rose hydrosol volatiles was carried out for extrapolating the current study to humans. The present results suggest that rose hydrosol exerts significant protective properties in diabetes mellitus and has no toxic effect on all studied systems in healthy test groups.
Journal Article